Penicillin

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation of NRX-101 in Complicated Urinary Tract Infection and Pyelonephritis

Retrieved on: 
Tuesday, January 16, 2024
Intellectual property, Death, Clostridioides difficile infection, Patient, Research, DSM-IV codes, Hospital, Health, Urine, Dark Enlightenment, Colitis, Tuberculosis, UTI, Clostridioides difficile, DCS, Tetracycline, QIDP, Risk, Infection, Cephalosporin, Pulmonary fibrosis, Sepsis, FDA, Priority review, Penicillin, New Drug Application, Pyelonephritis, Urinary tract infection, Literature, Contra, NMDA, CNS, Pharmaceutical industry

Receipt of QIDP designation confers Priority Review, and critically, five additional years of data-exclusivity to NRX-101's already strong Intellectual Property position.

Key Points: 
  • Receipt of QIDP designation confers Priority Review, and critically, five additional years of data-exclusivity to NRX-101's already strong Intellectual Property position.
  • The FDA also granted NRX-101 Fast Track designation for cUTI, which additionally allows for rolling submission of the Company's New Drug Application.
  • On the basis of this advance, NRx is seeking partners with active involvement in urology, infectious disease and/or women's health for commercialization of NRX-101.
  • NRx thanks the US FDA for its rapid award of QIDP designation for cUTI and pyelonephritis.

Human medicines European public assessment report (EPAR): Fetcroja, cefiderocol, Date of authorisation: 23/04/2020, Revision: 8, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Urine, Medical Subject Headings, Diarrhea, Marketing, Agency, INN, Infection, Allergy, ATC, Carbapenem, International, Cough, Nausea, Language, Urinary tract infection, European Medicines Agency, Cilastatin, Bloodstream infections, Imipenem, Select, Patient, Iron, Bacteria, Anatomy, Penicillin, Vomiting, IIA, Gram-negative bacteria, Medical device

Human medicines European public assessment report (EPAR): Fetcroja, cefiderocol, Date of authorisation: 23/04/2020, Revision: 8, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Fetcroja, cefiderocol, Date of authorisation: 23/04/2020, Revision: 8, Status: Authorised

Sandoz inaugurates new antibiotic production plant in Austria and new biosimilar development center in Germany

Retrieved on: 
Friday, November 10, 2023
Investment, Penicillin, EUR, API, Media release, Fine chemical, Generic drug, Kundl, Novartis, Holzkirchen

The inauguration of a new facility for production of penicillin at Kundl, Austria, and a new biosimilar development center in Holzkirchen, Germany, reaffirm the dual Sandoz commitment to ensuring sustainable access to quality antibiotics and spearheading development of biosimilars.

Key Points: 
  • The inauguration of a new facility for production of penicillin at Kundl, Austria, and a new biosimilar development center in Holzkirchen, Germany, reaffirm the dual Sandoz commitment to ensuring sustainable access to quality antibiotics and spearheading development of biosimilars.
  • Sandoz has the only major remaining vertically-integrated production network for penicillins in Europe; penicillins are the leading category of antibiotics worldwide.
  • Antibiotics are the backbone of modern medicine and the Kundl plant is a testament to the resilience of European manufacturing.
  • The new development center in Holzkirchen will become a global hub for biosimilar expertise."

Do you think you have a penicillin allergy? You might be wrong

Retrieved on: 
Wednesday, November 8, 2023
People, Allergy, Anaphylaxis, Research, Child, Amoxicillin, Roger Hawkins (drummer), Time, Periodic breathing, Burns, Health, Skin test, Solution, Blister, Infection, Inflammation, Nausea, Rash, Diarrhea, Risk, Penicillin, Ear, Food security, Bacteria, Population, Patient, Hospital, Communication, System, Clostridioides difficile, Antibiotics, Cochineal, Vaccine, Pig, Health insurance, Nursing

Originally derived from a fungus, penicillin antibiotics such as amoxicillin are used to treat common infections, including chest, sinus, ear, urinary tract and skin infections.

Key Points: 
  • Originally derived from a fungus, penicillin antibiotics such as amoxicillin are used to treat common infections, including chest, sinus, ear, urinary tract and skin infections.
  • Up to 20% of Australians admitted in hospital say they have a penicillin allergy.
  • Read more:
    Weekly Dose: penicillin, the mould that saves millions of lives

Why does it matter?

  • People who mistakenly think they’re allergic to penicillin may not get the most effective or safest antibiotics to treat their infection.
  • They are also at greater risk of developing multidrug-resistant infections or “superbugs”.
  • People who receive second-line antibiotics are more likely to have complications, such as antibiotic-induced gut infections.

Why do people think they’re allergic?

  • They may have experienced side effects from penicillin, such as nausea or diarrhoea.
  • An Epstein-Barr viral infection treated with amoxicillin, for example, causes a fine, red rash.
  • But there is no evidence penicillin allergy is inherited.
  • Then there are people who have had a genuine and serious reaction to penicillin.

Testing for penicillin


When someone says they have a penicillin allergy, we first get them to explain what happened with the reaction, including to what antibiotic, in what context and how severe it was. Then we perform skin tests to further assess the person’s risk of reaction. If skin tests are negative, we can then give the patient the penicillin in question under supervision (a “challenge”) to see if they react.

  • Our study followed 195 patients who reported a penicillin allergy across six Sydney hospitals.
  • In the first phase, we assessed 85 people and found 82% weren’t allergic to penicillin.
  • In our study, eight weeks after their test, just 54% of participants in phase one correctly knew their penicillin allergy status.

Reducing long waits for allergy tests

  • The wait time from someone first being referred to an allergy clinic to having testing can be up to two years.
  • We need to improve access to testing and also look at when people can access allergy services.
  • We also need to ensure the results of allergy tests translate to the real world so people know their true allergy status.
  • Winnie Tong has received funding from Maridulu Budyari Gumal, the Sydney Partnership for Health, Education, Research and Enterprise (SPHERE), Triple I Clinical Academic Group seed grant 2017, and the Balnaves Foundation.
  • The authors would like to acknowledge Professor Andrew Carr, their collaborators and participants on this project.

Most people who think they are allergic to penicillin aren't

Retrieved on: 
Wednesday, October 4, 2023
Infection, Review, Allergy, Rash, Ear, Life, Clostridioides difficile, Method, Royal Pharmaceutical Society, Fever, MRSA, Germ, Medicine, Diarrhea, Sickle cell disease, Vomiting, Death, Pharmacist, Anti-transglutaminase antibodies, Patient, Swelling, Anaphylaxis, Child, Risk, Nursing, Amoxicillin, Health, Penicillin, Bacteria, Throat, Roger Hawkins (drummer), GP, Pneumonia, Mouth, Respiratory failure, Pharmaceutical industry, Antibiotics, Vaccine, Enterovirus

Allergies vary between us, but someone allergic to penicillin typically develops a rash, itching and swelling.

Key Points: 
  • Allergies vary between us, but someone allergic to penicillin typically develops a rash, itching and swelling.
  • Typically, it is made when using penicillin to treat a feverish child with signs of an infected ear or throat.
  • This is done because someone allergic to penicillin typically responds badly to the next dose of penicillin, which can include the potentially lethal condition known as anaphylaxis.
  • If you think you have a penicillin allergy it would be wise to discuss and confirm this with your doctor.

Hong Kong Takes Center Stage at Asia’s 50 Best Bars 2023 As COA Claims Top Spot for Third Year Running

Retrieved on: 
Thursday, July 20, 2023
Retail, Restaurant, Bar, Vacation, Destinations, Travel, Tourist Attractions, Taste, Partnership, Old man, Hong Kong Tourism Board, Eating, Multimedia, Old, Drinking, Creativity, City, Content, COA, Nightclub, Film industry, Penicillin

Over 800 of Asia’s elite bartenders and drinks industry experts gathered in Hong Kong on July 18 for the unveiling of Asia’s 50 Best Bars 2023 .

Key Points: 
  • Over 800 of Asia’s elite bartenders and drinks industry experts gathered in Hong Kong on July 18 for the unveiling of Asia’s 50 Best Bars 2023 .
  • Jay Khan, owner of COA in Hong Kong, said: “Of the three number ones, this one means the most.
  • Congratulations to Hong Kong and the team at COA for taking the No.1 spot as well as all of the bars on this year’s list.”
    In addition to COA claiming the top spot, 8 Hong Kong bars made the 2023 list.
  • The arrival of Asia’s 50 Best Bars in Hong Kong reinforces the position of the city’s bar scene as one of the most exciting in the world.

Hong Kong Takes Centre Stage At Asia's 50 Best Bars 2023 As COA Claims Top Spot For Third-Year Running

Retrieved on: 
Wednesday, July 19, 2023
Taste, Partnership, Food, Hong Kong Tourism Board, Eating, Old, Drinking, Creativity, City, Content, COA, Film industry, Nightclub, Penicillin

Brought to Hong Kong for the first time by the Hong Kong Tourism Board in partnership with Asia's 50 Best Bars, the awards celebrated the continued success of Asia's thriving bar landscape while showcasing Hong Kong's vibrant bar scene to the region's top bartending talent.

Key Points: 
  • Brought to Hong Kong for the first time by the Hong Kong Tourism Board in partnership with Asia's 50 Best Bars, the awards celebrated the continued success of Asia's thriving bar landscape while showcasing Hong Kong's vibrant bar scene to the region's top bartending talent.
  • Jay Khan, owner of COA in Hong Kong, said: "Of the three number ones, this one means the most.
  • In addition to COA taking out the top spot, Asia's 50 Best Bars once again recognized the depth and breadth of Hong Kong's world-class bar scene, with 8 homegrown bars featuring on the 2023 list.
  • The arrival of Asia's 50 Best Bars in Hong Kong reinforces the city's bar scene position as one of the most exciting in the world.

Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious Diseases

Retrieved on: 
Thursday, May 11, 2023
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases, Clinical Trials, Priority review, Nephrotoxicity, Safety, Infection, Antimicrobial spectrum, New Drug Application, NDA, World Health Organization, Colistin, Acinetobacter, Gram-negative bacteria, Centers for Disease Control and Prevention, CDC, Acinetobacter baumannii, The Lancet, Aminoglycoside, Incidence, Death, Rutgers University, Cephalosporin, Robert Wood Johnson Medical School, Patient, Chronic kidney disease, Penicillin, Division, Carbapenem, Disease, PDUFA, Mortality, Nursing care plan, WHO, FDA, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Gene, MPH, Food, Pharmaceutical industry, Vaccine, MD

The study – Efficacy and Safety of Sulbactam-Durlobactam vs. Colistin for the Treatment of Patients with Serious Infections due to Acinetobacter Baumannii-Calcoaceticus Complex: a multicentre, randomised, active-controlled, Phase 3, non-inferiority clinical trial (ATTACK) – was first published online on May 11.

Key Points: 
  • The study – Efficacy and Safety of Sulbactam-Durlobactam vs. Colistin for the Treatment of Patients with Serious Infections due to Acinetobacter Baumannii-Calcoaceticus Complex: a multicentre, randomised, active-controlled, Phase 3, non-inferiority clinical trial (ATTACK) – was first published online on May 11.
  • The Phase 3 trial evaluated the safety and efficacy of sulbactam-durlobactam versus colistin in patients with infections caused by Acinetobacter.
  • In the trial, sulbactam-durlobactam demonstrated statistical non-inferiority versus colistin for the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections and a significant difference in clinical cure rates.
  • The sulbactam-durlobactam NDA has a Prescription Drug User Fee Act (PDUFA) target action date of May 29, 2023.

Sulbactam-Durlobactam Unanimously Recommended for Approval by FDA Advisory Committee

Retrieved on: 
Monday, April 17, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Priority review, Nephrotoxicity, Infection, Antimicrobial spectrum, New Drug Application, NDA, Colistin, Acinetobacter, Gram-negative bacteria, Centers for Disease Control and Prevention, Committee, CDC, Acinetobacter baumannii, Aminoglycoside, Incidence, Death, Cephalosporin, MD, Patient, Chronic kidney disease, Penicillin, Carbapenem, Disease, PDUFA, Mortality, WHO, Therapy, Gene, Food, Safety, Pharmaceutical industry, Vaccine

The FDA will take the Committee’s recommendation into consideration when it makes a final determination.

Key Points: 
  • The FDA will take the Committee’s recommendation into consideration when it makes a final determination.
  • Infections caused by drug-resistant Acinetobacter are serious and life-threatening conditions associated with high morbidity and mortality1 and long, expensive hospital stays.
  • Globally, Acinetobacter baumannii was among the top six leading pathogens for deaths associated with resistance in 20193.
  • Carbpenem-resistant Acinetobacter is considered a Priority 1 pathogen by the World Health Organization (WHO)4.

Saudi Arabia Antibiotics Markets, Competition, Forecast & Opportunities, 2027 - Cephalosporin, Penicillin, Amoxicillin, Azithromycin, Clindamycin, Tetracycline - ResearchAndMarkets.com

Retrieved on: 
Friday, January 27, 2023
Infectious Diseases, Pharmaceutical, Health, Capsule, Administration, Penicillin, Urinary tract infection, Infection, Government, Virus, Viral, Investment, Cephalosporin, COVID-19, Disorder, Saudi Food and Drug Authority, Drug development, Market, Route of administration, Certification, Research, Ministry, Death, SFDA, Antibody, Disease, Sanofi, Growth, Spectrum, Bacteria, Clindamycin, Tablet, Grindeks, Pharmaceutical industry, Vaccine, Arms industry, Azithromycin, Amoxicillin, Sepsis, Tetracycline

Saudi Arabia antibiotics market is anticipated to register growth with an impressive CAGR in the forecast period, 2023-2027, on the account of increasing instances of infectious diseases.

Key Points: 
  • Saudi Arabia antibiotics market is anticipated to register growth with an impressive CAGR in the forecast period, 2023-2027, on the account of increasing instances of infectious diseases.
  • Saudi Arabia pharmaceutical industry grossed USD8.35 billion in the year 2019 that further registered growth of USD10.19 billion in 2020.
  • promotes the requirement for the antibiotics and thus supports the growth of the Saudi Arabia antibiotics market in the next five years.
  • Company Profiles: Detailed analysis of the major companies present in Saudi Arabia antibiotics market.